Tryptamine induces axonopathy and mitochondriopathy mimicking neurodegenerative diseases via tryptophanyl-tRNA deficiency

Current Alzheimer Research

Volumn 10, Issue 9, 2013, Pages 987-1004

  Paley, Elena L ^a,b   Perry, George ^c   Sokolova, Olga ^d  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b Expert BioMed Inc   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d BRANDEIS UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Axonal swellings; Mitochondria derived vesicles; Mitochondrial fission; Tryptamine neurotoxicity and nephrotoxicity; Tryptophanyl tRNA synthetase

Indexed keywords

TRYPTAMINE; TRYPTOPHAN TRANSFER RNA LIGASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CONVULSION; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPILEPSY; HIPPOCAMPUS; HUMAN; HUMAN CELL; KIDNEY CELL; MALE; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MITOCHONDRION SWELLING; MOUSE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NERVE FIBER MEMBRANE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AXONS; HIPPOCAMPUS; MICE; MITOCHONDRIA; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; NEURONS; TRYPTAMINES; TRYPTOPHAN-TRNA LIGASE;

EID: 84888261878     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113106660164     Document Type: Article

References (84)

1. Mousseau DD. Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders. Metab Brain Dis 8(1): 1-44 (1993).
2. Miller CA, Expression of the human aryl hydrocarbon receptor complex in yeast. Activation of transcription by indole compounds. J Biol Chem 272(52): 32824-32829 (1997).
3. Heath-Pagliuso S, Rogers WJ, Tullis K, Seidel SD, Cenijn PH, Brouwer A, et al. Activation of the Ah receptor by tryptophan and tryptophan metabolites. Biochemistry 37(33): 11508-11515 (1998).
4. Stute R, Petrridis K, Steinhart H, Biernoth G. Biogenic amines in fish and soy sauces. Eur Food Res Technol 215(2): 101-107 (2002).
5. Di FS, Li Q, Leech MJ, Schuster F, Emans N, Fischer R, et al. Targeting tryptophan decarboxylase to selected subcellular compartments of tobacco plants affects enzyme stability and in vivo function and leads to a lesion-mimic phenotype. Plant Physiol 129(3): 1160-1169 (2002).
6. Paley EL, Denisova G, Sokolova O, Posternak N, Wang X, Brownell AL. Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models. Neuromolecular Med 9(1): 55-82 (2007).
7. Martin WR, Sloan JW, Buchwald WF, Clements TH. Neurochemi-cal evidence for tryptaminergic ascending and descending pathways in the spinal cord of the dog. Psychopharmacologia 43(2): 131-134 (1975).
8. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323(5916): 934-937 (2009).
9. Goterries CG, Magnusson T. Excretion of tryptamine in man during treatment with MAO inhibitors. Acta Psychiatr Scand 38: 223-226 (1962).
10. Cascio CS, Kellar KJ. Tetrahydro-beta-carbolines: affinities for tryptamine and serotonergic binding sites. Neuropharmacology 21(11): 1219-1221 (1982).
11. Bosin TR, Hixson EJ, Maickel RP. Pressor effects of tryptamine analogues. Br J Pharmacol 56(1): 25-27 (1976).
12. Krstic MK, Djurkovic D. Analysis of the cardiovascular responses to central injection of tryptamine in rats. Neuropharmacology 24(6): 517-525 (1985).
13. Clineschmidt BV, Lotti VJ. Indoleamine antagonists: relative potencies as inhibitors of tryptamine- and 5-hydroxytryptophan-evoked responses. Br J Pharmacol 50(2): 311-313 (1974).
14. Van OD, Megens A, Meert T, Luyten WH, Leysen JE. Functional study of rat 5-HT2A receptors using antisense oligonucleotides. J Neurochem 85(5): 1087-1100 (2003).
15. Yamada J, Sugimoto Y, Horisaka K. The behavioural effects of intravenously administered tryptamine in mice. Neuropharmacol-ogy 26(1): 49-53 (1987).
16. Yamada J, Sugimoto Y, Horisaka K. Pharmacological analysis of the variation in behavioural responses to tryptamine in five strains of mice. Eur J Pharmacol 140(3): 323-330 (1987).
17. Yamada J, Sugimoto Y, Horisaka K. The evidence for the involvement of the 5-HT1A receptor in 5-HT syndrome induced in mice by tryptamine. Jpn J Pharmacol 51(3): 421-424 (1989).
18. Marley E, Vane JR. Tryptamines and spinal cord reflexes in cats. Br J Pharmacol Chemother 31(3): 447-465 (1967).
19. Larson AA. Hyperalgesia produced by the intrathecal administration of tryptamine to rats. Brain Res 265(1): 109-117 (1983).
20. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62(10): 1556-1560 (2005).
21. Martin WR, Sloan JW, Vaupel DB. Tryptamine in the brain and spinal cord: its role in the LSD response. Psychopharmacol Bull 12(4): 31-32 (1976).
22. Prevedello MR, Ritta MN, Cardinali DP. Fast axonal transport in rat sciatic nerve. Inhibition by pineal indoles. Neurosci Lett 13(1): 29-34 (1979).
23. Karasawa A, Ogihara M, Ishitani R. 3Htryptamine binding to reconstituted fraction of acidic lipids. J Pharmacobiodyn 10(2): 78-84 (1987).
24. Han X. Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics. J Neurochem 103(1): 171-179 (2007).
25. Buschard K, Hoy M, Bokvist K, Olsen HL, Madsbad S, Fredman P, et al. Sulfatide controls insulin secretion by modulation of ATP-sensitive K(+)-channel activity and Ca(2+)-dependent exocytosis in rat pancreatic beta-cells. Diabetes 51(8): 2514-2521 (2002).
26. Yamada J, Sugimoto Y, Kimura I, Takeuchi N, Horisaka K. The activation of serotonin receptors by tryptamine induces hyperinsu-linemia in mice. Eur J Pharmacol 181(3): 319-322 (1990).
27. Koshima H, Honke S. Chiral Bimolecular Crystallization of Tryp-tamine and Achiral Carboxylic Acids. J Org Chem 64(3): 790-793 (1999).
28. Miklossy J, Taddei K, Martins R, Escher G, Kraftsik R, Pillevuit O et al. Alzheimer disease: curly fibers and tangles in organs other than brain. J Neuropathol Exp Neurol 58(8): 803-814 (1999).
29. Kisselev LL, Favorova OO, Kovaleva GK. Tryptophanyl-tRNA synthetase from beef pancreas. Methods Enzymol 59: 234-257 (1979).
30. Paley EL, Baranov VN, Alexandrova NM, Kisselev LL. Tryp-tophanyl-tRNA synthetase in cell lines resistant to tryptophan analogs. Exp Cell Res 195(1): 66-78 (1991).
31. Paley EL. Tryptamine-mediated stabilization of tryptophanyl-tRNA synthetase in human cervical carcinoma cell line. Cancer Lett 137(1): 1-7 (1999).
32. Farabaugh PJ. Programmed translational frameshifting. Microbiol Rev 60(1): 103-134 (1996).
33. Paley EL. A mammalian tryptophanyl-tRNA synthetase is associated with protein kinase activity. Eur J Biochem 244(3): 780-788 (1997).
34. Paley EL, Smelyanski L, Malinovskii V, Subbarayan PR, Berdi-chevsky Y, Posternak N, et al. Mapping and molecular characterization of novel monoclonal antibodies to conformational epitopes on NH2 and COOH termini of mammalian tryptophanyl-tRNA synthetase reveal link of the epitopes to aggregation and Alzheimer's disease. Mol Immunol 44(4): 541-557 (2007).
35. Biagiotti T, D'Amico M, Marzi I, Di GP, Arcangeli A, Wanke E, et al. Cell renewing in neuroblastoma: electrophysiological and im-munocytochemical characterization of stem cells and derivatives. Stem Cells 24(2): 443-453 (2006).
36. Paley EL. Tryptamine-Induced Tryptophanyl-tRNAtrp Deficiency in Neurodifferentiation and Neurodegeneration Interplay: Progenitor Activation with Neurite Growth Terminated in Alzheimer's Disease Neuronal Vesicularization and Fragmentation. J Alzheimers Dis 26(2) (2011).
37. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mito-chondrial fragmentation in neurodegeneration. Nat Rev Neurosci 9(7): 505-518 (2008).
38. Barsoum MJ, Yuan H, Gerencser AA, Liot G, Kushnareva Y, Gra-ber S, et al. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J 25(16): 3900-3911 (2006).
39. McMahon HT, Gallop JL. Membrane curvature and mechanisms of dynamic cell membrane remodelling. Nature 438(7068): 590-596 (2005).
40. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307(5713):1282-1288 (2005).
41. Saito M, Serikyaku S, Ishitani R. Effect of phospholipase A2 on temperature-induced high-affinity [3H]tryptamine binding sites in rat brain. Jpn J Pharmacol 56(4): 413-419 (1991).
42. Iseki K, Sugawara M, Saitoh N, Miyazaki K. The transport mechanisms of organic cations and their zwitterionic derivatives across rat intestinal brush-border membrane. 1. Binding characteristics to the bio- and lipid-membranes. Biochim Biophys Acta 1146(1): 121-126 (1993).
43. Vance JE. Newly made phosphatidylserine and phosphatidyletha-nolamine are preferentially translocated between rat liver mitochondria and endoplasmic reticulum. J Biol Chem 266(1): 89-97 (1991).
44. Ishitani R, Kimura M, Takeichi M, Chuang DM. Tryptamine induces phosphoinositide turnover and modulates adrenergic and muscarinic cholinergic receptor function in cultured cerebellar granule cells. J Neurochem 63(6): 2080-2085 (1994).
45. Ledeen RW, Golly F, Haley JE. Axon-myelin transfer of phosphol-ipids and phospholipid precursors. Labeling of myelin phosphoi-nositides through axonal transport. Mol Neurobiol 6(2-3): 179-190 (1992).
46. Herrera F, Martin V, Carrera P, Garcia-Santos G, Rodriguez-Blanco J, Rodriguez C, et al. Tryptamine induces cell death with ultrastructural features of autophagy in neurons and glia: Possible relevance for neurodegenerative disorders. Anat Rec A Discov Mol Cell Evol Biol 288(9): 1026-1030 (2006).
47. Popenko VI, Cherny NE, Beresten SF, Ivanova JL, Filonenko VV, Kisselev LL. Immunoelectron microscopic location of tryptophanyl-tRNA synthetase in mammalian, prokaryotic and archae-bacterial cells. Eur J Cell Biol 62(2): 248-258 (1993).
48. Jorgensen R, Sogaard TM, Rossing AB, Martensen PM, Justesen J. Identification and characterization of human mitochondrial tryp-tophanyl-tRNA synthetase. J Biol Chem 275(22): 16820-16826 (2000).
49. Bridge KE, Berg N, Adalbert R, Babetto E, Dias T, Spillantini MG, et al. Late onset distal axonal swelling in YFP-H transgenic mice. Neurobiol Aging 30(2): 309-321 (2009).
50. Yagashita S. Ultrastructural observations on axonal swelling in the human gracile nucleus. Virchows Arch A Pathol Anat Histol 382(2): 217-226 (1979).
51. Davis L, Dou P, DeWit M, Kater SB. Protein synthesis within neuronal growth cones. J Neurosci 12(12): 4867-4877 (1992).
52. Bossy-Wetzel E, Barsoum MJ, Godzik A, Schwarzenbacher R, Lipton SA. Mitochondrial fission in apoptosis, neurodegeneration and aging. Curr Opin Cell Biol 15(6): 706-716 (2003).
53. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21(9): 3017-3023 (2001).
54. Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, et al. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease. J Alzheimers Dis 20(2): S401-S412 (2010).
55. Amchenkova AA, Bakeeva LE, Chentsov YS, Skulachev VP, Zo-rov DB. Coupling membranes as energy-transmitting cables. I. Filamentous mitochondria in fibroblasts and mitochondrial clusters in cardiomyocytes. J Cell Biol 107(2): 481-495 (1988).
56. Lee CW, Peng HB. Mitochondrial clustering at the vertebrate neu-romuscular junction during presynaptic differentiation. J Neurobiol 66(6): 522-536 (2006).
57. Andrade-Navarro MA, Sanchez-Pulido L, McBride HM. Mitochondrial vesicles: an ancient process providing new links to peroxisomes. Curr Opin Cell Biol 21(4): 560-567 (2009).
58. Hotamisligil GS, Breakefield XO. Human monoamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet 49(2): 383-392 (1991).
59. Favorova OO, Zargarova TA, Rukosuyev VS, Beresten SF, Kisselev LL. Molecular and cellular studies of tryptophanyl-tRNA syn-thetases using monoclonal antibodies. Remarkable variations in the content of tryptophanyl-tRNA synthetase in the pancreas of different mammals. Eur J Biochem 184(3): 583-588 (1989).
60. Sacconi S, Salviati L, Nishigaki Y, Walker WF, Hernandez-Rosa E, Trevisson E, et al. A functionally dominant mitochondrial DNA mutation. Hum Mol Genet 17(12): 1814-1820 (2008).
61. Mkaouar-Rebai E, Chamkha I, Kammoun F, Kammoun T, Aloulou H, Hachicha M, et al. Two new mutations in the MT-TW gene leading to the disruption of the secondary structure of the tRNA(Trp) in patients with Leigh syndrome. Mol Genet Metab 97(3): 179-184 (2009).
62. Silvestri G, Rana M, DiMuzio A, Uncini A, Tonali P, Servidei S. A late-onset mitochondrial myopathy is associated with a novel mito-chondrial DNA (mtDNA) point mutation in the tRNA(Trp) gene. Neuromuscul Disord 8(5): 291-295 (1998).
63. Silvestri G, Mongini T, Odoardi F, Modoni A, deRosa G, Doriguzzi C, et al. A new mtDNA mutation associated with a progressive encephalopathy and cytochrome c oxidase deficiency. Neurology 54(8): 1693-1696 (2000).
64. Maniura-Weber K, Taylor RW, Johnson MA, Chrzanowska-Lightowlers Z, Morris AA, Charlton CP, et al. A novel point mutation in the mitochondrial tRNA(Trp) gene produces a neurogastro-intestinal syndrome. Eur J Hum Genet 12(6): 509-512 (2004).
65. Nelson I, Hanna MG, Alsanjari N, Scaravilli F, Morgan-Hughes JA, Harding AE. A new mitochondrial DNA mutation associated with progressive dementia and chorea: a clinical, pathological, and molecular genetic study. Ann Neurol 37(3): 400-403 (1995).
66. Malfatti E, Cardaioli E, Battisti C, Da PP, Malandrini A, Rufa A, et al. A novel point mutation in the mitochondrial tRNA((Trp)) gene produces late-onset encephalomyopathy, plus additional features. J Neurol Sci 297(1-2): 105-108 (2010).
67. Jordanova A, Irobi J, Thomas FP, Van DP, Meerschaert K, Dewil M, et al. Disrupted function and axonal distribution of mutant tyro-syl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet 38(2): 197-202 (2006).
68. Motley WW, Talbot K, Fischbeck KH. GARS axonopathy: not every neuron's cup of tRNA. Trends Neurosci 33(2): 59-66 (2010).
69. Latour P, Thauvin-Robinet C, Baudelet-Mery C, Soichot P, Cusin V, Faivre L, et al. A major determinant for binding and aminoacy-lation of tRNA(Ala) in cytoplasmic Alanyl-tRNA synthetase is mutated in dominant axonal Charcot-Marie-Tooth disease. Am J Hum Genet 86(1): 77-82 (2010).
70. McLaughlin HM, Sakaguchi R, Liu C, Igarashi T, Pehlivan D, Chu K, et al. Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. Am J Hum Genet 87(4): 560-566 (2010).
71. Scheper GC, van der KT, van Andel RJ, van Berkel CG, Sissler M, Smet J, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet 39(4): 534-539 (2007).
72. Riley LG, Cooper S, Hickey P, Rudinger-Thirion J, McKenzie M, Compton A, et al. Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and si-deroblastic anemia--MLASA syndrome. Am J Hum Genet 87(1): 52-59 (2010).
73. Monaco F, Fumero S, Mondino A, Mutani R. Plasma and cerebro-spinal fluid tryptophan in multiple sclerosis and degenerative diseases. J Neurol Neurosurg Psychiatry 42(7): 640-641 (1979).
74. Koskiniemi ML. Deficient intestinal absorption of L-tryptophan in progressive myoclonus epilepsy without Lafora bodies. J Neurol Sci 47(1): 1-6 (1980).
75. Pratt JA, Jenner P, Johnson AL, Shorvon SD, Reynolds EH. Anti-convulsant drugs alter plasma tryptophan concentrations in epileptic patients: implications for antiepileptic action and mental function. J Neurol Neurosurg Psychiatry 47(10): 1131-1133 (1984).
76. Fekkes D, van der Cammen TJ, van Loon CP, Verschoor C, van HF, de KI, et al. Abnormal amino acid metabolism in patients with early stage Alzheimer dementia. J Neural Transm 105(2-3): 287-294 (1998).
77. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryp-tophan degradation and immune activation in Alzheimer's disease. J Neural Transm 107(3): 343-353 (2000).
78. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 467: 133-138 (1999).
79. Widner B, Leblhuber F, Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm 109(2): 181-189 (2002).
80. Demling J, Langer K, Mehr MQ. Age dependence of large neutral amino acid levels in plasma. Focus on Tryptophan. Adv Exp Med Biol 398: 579-582 (1996).
81. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73(20): 1662-1669 (2009).
82. Valles F, Fiandaca MS, Eberling JL, Starr PA, Larson PS, Christine CW, et al. Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery 67(5): 1377-1385 (2010).
83. Marien MR, Gerber R, Boyar WC, Altar CA. Injections of deuter-ated tryptamine into the nucleus accumbens of the rat: effects on locomotor activity and monoamine metabolism. Neuropharmacol-ogy 26(10): 1481-1488 (1987).
84. Paley EL. Tryptamine-induced tryptophanyl-tRNAtrp deficiency in neurodifferentiation and neurodegeneration interplay: progenitor activation with neurite growth terminated in Alzheimer's disease neuronal vesicularization and fragmentation. J Alzheimers Dis 25: 1-36 (2011).